Characterization of naïve, memory and effector T cells in progressive multiple sclerosis

Area of Science:

• Immunology
• Neuroimmunology
• T cell biology

Background:

• Multiple Sclerosis (MS) is a chronic inflammatory disease of the central nervous system.
• T cell subsets, including naïve, central memory (CM), effector memory (EM), and terminally differentiated effector memory (TEMRA) cells, play critical roles in immune responses.
• The expression of CD49d and CD26 on T cells is associated with immune cell trafficking and function, but their specific roles in MS pathogenesis require further elucidation.

Purpose of the Study:

• To characterize naïve, CM, EM, and TEMRA CD4+ and CD8+ T cells and their expression of CD49d and CD26 in the peripheral blood of MS patients and healthy controls.
• To investigate the impact of natalizumab, a disease-modifying therapy for MS, on these T cell subsets and their marker expression.

Main Methods:

• Flow cytometry was used to analyze peripheral blood mononuclear cells (PBMCs).
• Characterization of T cell subsets (naïve, CM, EM, TEMRA) for both CD4+ and CD8+ T cells.
• Quantification of CD49d and CD26 expression on these T cell subsets.

Main Results:

• Increased frequencies of CD26+ CD28+ CD4+ TEMRA T cells were observed in all MS subtypes.
• Elevated levels of CD26+ CD28+ CD8+ TEMRA T cells were found in relapsing-remitting and secondary progressive MS.
• In progressive MS, CD49d+ CM T cells were decreased. Natalizumab treatment increased the overall number of circulating T cell subsets but decreased the frequency of most subsets expressing CD49d and CD26.

Conclusions:

• Specific T cell subsets, particularly CD4+ and CD8+ TEMRA cells expressing CD26, are altered in the peripheral blood of MS patients.
• CD49d+ CM T cells may be depleted in progressive MS.
• Natalizumab influences T cell distribution and marker expression, suggesting complex immunomodulatory effects in MS treatment.